Navigation Links
Redwood Bioscience Appoints Peter Van Vlasselaer, PhD as Executive Chairman
Date:10/3/2011

EMERYVILLE, Calif., Oct. 3, 2011 /PRNewswire/ -- Redwood Bioscience, a biopharmaceutical company developing a rational protein-chemical design technology for optimizing drug conjugates, announced the appointment of Peter Van Vlasselaer, PhD as Executive Chairman to Redwood's Board of Directors.  In this role, Dr. Van Vlasselaer will be actively guiding Redwood on drug and platform development as well as corporate strategy.  Dr. Van Vlasselaer has been involved in the start-up of four biotechnology companies and brings more than 20 years of senior management experience to Redwood.

Currently, Dr. Van Vlasselaer is the Executive Chairman of iPierian, where he was the interim CEO earlier this year.  He previously served as the founding CEO of Arresto Biosciences which was acquired by Gilead Sciences in December 2010.  Prior to launching Arresto, Dr. Van Vlasselaer was the CEO of Avidia which also had a successful exit though its sale to Amgen in October 2006.  Before that he was involved in the start-up of InterMune and Dendreon where he served as Senior Vice President of Technical Operations and Vice President of Development, respectively.  He holds a bachelor degree in zoology, a PhD in immunology from the University of Leuven in Belgium and conducted post-doctoral research at Stanford University and at DNAX Research Institute.

During his career, Dr. Van Vlasselaer has contributed to the development of multiple biologic products and small molecules for treating diseases including cancer, inflammation, infectious diseases and fibrosis.  He has authored several peer reviewed scientific articles and book chapters and is the inventor on more than 30 patents.

"We are thrilled to welcome Peter to the Executive Chairman role at Redwood," said Karen Boezi, CEO of Redwood.  "His expertise in drug development, operations, corporate strategy and business development will be extremely valuable to the Company."

"We are very pleased to be able to access Peter's proven abilities in shepherding novel technologies from research into the clinic and driving value for investors," stated David Rabuka, co-founder, President & Chief Scientific Officer.

"Redwood stands out as a biotechnology company poised to significantly advance the field of drug conjugates," said Dr. Van Vlasselaer.  "The Company's site specific protein modification technology overcomes the challenges associated with conjugating biologics to synthetic molecules.  By providing control over cargo placement, number and orientation as well as good conjugation efficiency, Redwood is able to generate well defined conjugate libraries for identification of superior antibody-drug conjugates and peptide therapeutics."  

About Redwood Bioscience, Inc.

Redwood Bioscience, an Emeryville, CA based company, is developing a rational protein-chemical design technology to optimize antibody drug conjugates and peptide therapeutics.  The Company's site specific protein modification platform provides unparalleled control over cargo placement on a protein, cargo orientation and stoichiometry, enabling the creation of conjugate libraries from which homogenous compounds with optimal efficacy, safety, and half-life can be selected.  Redwood is located in Emeryville, CA.  For further information, please visit www.redwoodbioscience.com.


'/>"/>
SOURCE Redwood Bioscience, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Genesis Biosciences Announces New Hire and Promotions on Operational and Scientific Staff
2. Roka Bioscience Initiates External Trial for AOAC Certification
3. Sangamo BioSciences Announces Presentation at the 2011 UBS Global Life Sciences Conference
4. OBNs 2011 Annual Awards Dinner Celebrates UK Bioscience Success Stories
5. HUYA Bioscience International Forms Alliance With Zhejiang Chinese Medical University Life Science College
6. Ardea Biosciences Announces Positive End-of-Phase 2 Meetings with FDA for Lesinurad
7. Avantra Biosciences Changes Company Name to Courtagen Life Sciences, Inc.
8. BD Biosciences Announces Winners of Research Grant Program
9. 3-V Biosciences Appoints George W. Kemble, PhD, as Chief Scientific Officer
10. Numira Biosciences Names New Board Member
11. Ardea Biosciences Reports Recent Accomplishments and Second Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... BioAmber Inc. (NYSE: BIOA ) announced today that Jean-Francois Huc ... company,s COO, has been named President, effective immediately.  ... has overseen the construction, start-up and operation of the manufacturing plant ... Mitsui JV.  Fabrice has also been extensively involved in the negotiations ... ...
(Date:2/20/2017)... ... 20, 2017 , ... Salford-based Mettler Toledo Safeline, which employs ... processing and packaging industries, was runner-up for the Environmental Achievement Award, sponsored by ... or taken the most innovative steps to improve its environmental performance. , ...
(Date:2/20/2017)... ... February 20, 2017 , ... ... patients, prevent chest wall collapses in pre-term infants with respiratory distress, and ... total of $600,000 in funding through the ninth round of the University ...
(Date:2/20/2017)... 20, 2017  At the 2017 Health Information ... Orlando , IBM (NYSE: IBM ) ... IBM Chairman, President and CEO Ginni Rometty ... today from 8:30-10 am ET, broadcast live on ... Her remarks examine the advent of the Cognitive ...
Breaking Biology Technology:
(Date:1/26/2017)... , Jan. 26, 2017  Crossmatch, a leading ... a new solution aimed at combatting fraud, waste and ... was introduced at the Action on Disaster Relief conference ... meeting point for UN agencies and foreign assistance organizations ... Fraud, waste and abuse are a largely unacknowledged problem ...
(Date:1/23/2017)... , Jan. 23, 2017  The latest mobile ... smartphone prices have dropped dramatically. The quarterly average price ... 2013 to $276 in Q4 2016.  There are now ... price of $116, up from just 28 a year ... According to Maxine Most , Acuity Market ...
(Date:1/18/2017)... , Jan. 18, 2017 ... company that supports the entire spectrum of clinical ... been another record-breaking year for the organization in ... interest in MedNet,s eClinical products and services. The ... tremendous marketplace success of iMedNet ...
Breaking Biology News(10 mins):